Description: Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease; and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's ataxia, and VY-HTT01 for Huntington's disease, as well as VY-SMN101 for neuromuscular disease. The company has strategic collaborations with Genzyme Corporation and the University of Massachusetts Medical School. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Home Page: www.voyagertherapeutics.com
VYGR Technical Analysis
75 Sidney Street
Cambridge,
MA
02139
United States
Phone:
857 259 5340
Officers
| Name | Title |
|---|---|
| Mr. Robert W. Hesslein | Sr. VP & Gen. Counsel |
| Mr. G. Andre Turenne | Advisor |
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | Pres, CEO & Director |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Guangping Gao Ph.D. | Founder |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Dr. Phillip D. Zamore | Founder |
| Mr. Peter P. Pfreundschuh CPA | Chief Financial Officer |
| Ms. Robin Swartz | Chief Operating Officer |
| Mr. Todd Carter Ph.D. | Chief Science Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8246 |
| Price-to-Sales TTM: | 3.2706 |
| IPO Date: | 2015-11-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 101 |